One in three people prescribed medication for a serious or complex condition never takes a single dose. That number has been sitting in the medical literature for years, largely accepted as an unfortunate reality of how healthcare works. Forus, a New York-based health tech company, is betting $300 million in total funding that it doesn’t have to be.
The company announced a $150 million Series C on September 8, 2026, at a $3 billion valuation, tripling its value just months after closing its Series B. The round was led by Bain Capital Ventures, which has backed Forus since its seed stage. Every existing institutional investor also returned, including Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel.
What Forus actually does
Forus is a platform that assigns an AI agent to every prescription written through its system. That agent handles the entire path between a physician’s decision to prescribe and a patient starting treatment, including prior authorizations, insurance navigation, financial assistance programs, and pharmacy coordination. It works across every drug, payer, and pharmacy in the country, at no cost to providers or patients.
The agents are embedded directly into existing provider workflows. Each one reasons through a patient’s insurance coverage, medical history, and financial situation to determine what needs to happen next, drawing on clinical models and specialized sub-agents, and improving over time based on millions of prior cases. The goal is to make the process predictable enough that clinicians stop defaulting to older, easier-to-prescribe medications simply because they know they can actually get them to patients.
The problem it’s solving
The gap between a prescription and treatment is a well-documented failure point in U.S. healthcare. Prior authorization alone can take weeks. Financial assistance programs are fragmented and difficult to access. Specialty therapies, often the most effective options for complex conditions, require the most administrative work to secure. So physicians frequently reach for older treatments with more side effects and lower efficacy, not because of clinical preference, but because the path of least resistance is the path they know will work.
Some practices avoid entire disease areas because the administrative burden feels unmanageable. That means patients with conditions like inflammatory disease, certain cancers, or rare disorders may not even be offered the best treatment if their doctor’s office isn’t equipped to fight for it.
Dr. Brinda Dixit, a rheumatologist at Virginia Rheumatology Clinic in Chesapeake, Virginia, described the reality before Forus. “There were times a patient would come back after two or three months and tell me, ‘I haven’t even started the medication yet,'” she said. “With Forus, approvals for these medications come back in less than two days, and patients start treatment within a week or two. My patients are getting better faster because they are getting on therapy faster.”
Scale and reach
Forus is already operating across all 50 states, with providers using the platform to treat patients in 85% of U.S. residential ZIP codes. More than a third of providers in its first launched specialty have adopted the platform. The company plans to use this round to expand across all specialties and care settings, extend its AI agents’ capabilities across the full treatment pathway, and grow its team.
The biopharma side of the business is also growing. Forus is working with 9 of the top 15 global biopharma companies, along with a range of fast-growing biotechs. Because the platform sits at the center of how prescriptions actually move, it generates real-world data on where patients fall off, where provider workflows break down, and how medicines perform outside clinical trials. That data has real value for drug developers trying to design better studies or launch new therapies more effectively.
Why this raise matters
What’s notable about this round isn’t just the size. It’s that every existing investor came back, led by the same firm that wrote the first check. That kind of consensus across a cap table is rare, and it signals genuine confidence in both the model and the momentum.
- Platform active in all 50 states, reaching 85% of U.S. residential ZIP codes
- More than one-third of providers in the first launched specialty are using Forus
- Working with 9 of the top 15 global biopharma companies
- Free for both providers and patients
- Total funding exceeds $300 million
Kevin Zhang, General Partner at Bain Capital Ventures, put it plainly: “Forus is becoming how new medicine reaches people in America.” That might sound like investor enthusiasm. But given the scale the company has reached, and the structural problem it is addressing, it’s not far off as a description of what’s happening.